Become a Member

Topic Archives: Dendreon (DNDN)

  • AB4 Vaccine Ignites “Fierce Bidding War” for “Small Texas Lab?”

    What's Ernie Tremblay's CD19 AB4 Teaser All About?

    21 Comments Read More
  • written by reader Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection

    [Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

    1,002 Comments Read More
  • “Special Report: Cancer Killer Ready to Breakout” (Kramer)

    Today’s little tease comes to us from Hilary Kramer, who I briefly wrote about way back before the Gumshoe Vacation (that was the “Apple Killer,” which inspired a bit of discussion). This time she’s telling us that she’s got a “Cancer Killer” that’s ready to break out — and yes, killing cancer certainly sounds more […]

    28 Comments Read More
  • “Three Biotechs that Could Revolutionize Medicine (and make you RICH!)”

    “Move over Geron, Genentech and Osiris… The next generation in revolutionary biotechs has arrived. “(And they may be the only way to make money in this market!) “Each one of these 3 breakout stocks could realistically bring you gains of 128%, 185%, or even 422% in the next 6 months!” That heady promise introduces an […]

    13 Comments Read More
  • “The Next Stock to Crash”

    The Stansberry folks are predicting another collapse in a stock’s share price, and urging you to get on board with a short position (or, one imagines, a put option). The last time they urged an aggressive short position in their ads was with General Growth Properties, the mall REIT that they predicted would go bankrupt […]

    45 Comments Read More
  • “Wish I” Prostate Cancer Stock

    This is the second of Bottarelli’s three “Wish I” stocks — for more info, see the first one here. This second stock that exhibited a “pre emptive moving average” buy signal for Bottarelli’s analyst is a drug company of some sort. “$15.06 healthcare outfit out of Seattle, Washington that’s quietly developing one of the most […]

    5 Comments Read More
  • Comments

  • Never pay that much money for any advise service,I didn't subscribe to his microcap advisory and I new that he was teasi...

  • $ONCS ow 8-K filed > https://ir.oncosec.com/all-sec-filings/content/0001493152-18-000522/form8-k.htm If you have any q...

  • Roger: Here's how I view Immune Design. As of 2013-2014, the world was going like mad after tumor vaccine approaches to ...

  • Hard to believe any publication would be lauded for having pounded the table on Dendreon and Arena, Dendreon is the most...

  • I believe the author might read DR KSS and get some ideas from here and, when the timing is right, makes a recommendatio...

  • Before BIOC, ARTH and SCYX he nailed a couple other biotech winners, Dendreon for cancer and Arena Pharm for lorcaserin ...

  • Good biotech picks are virtually immune from economic conditions (but can be affected by political conditions). One exa...

  • One other thing that looks dubious to me about the JUNO situation is that, in addition to be helmed by formers of Dendre...

  • Changed Sleuth column to Watchlist, added date for $IBIO. Updated comment for $INO, added. Galena/NW Bio added with same...

  • INO from ZKSS 2/15/15 Spreadsheet: They have had some mildly good data, but it is still junk science: nonspecific effec...

  • Up at WSJBiotech’s Rally Fuels Bubble Fears As Valuations Skyrocket and Nasdaq Nears Record, Anxiety Builds A Gi...

  • We covered $INO in great depth last spring....the cattle prod DNA vaccine company. They are giving constructs via intram...

  • DR KSS Thank you for informing my ignorance,I would like to hear more of $BLCM. I wrongly assumed they were following ...

  • Elliot: our relative present Sedleckopenia has been noticed at least by me, and you are valued for your trenchant and th...

  • And former Dendreon CEO's new venture http://www.xconomy.com/wisconsin/2014/10/13/former-dendreon-ceo-gold-working-on-n...

  • DR KSS - I posted a reply/question on comment #136 re Dendreon. Just thought it might get buried....

  • Om: about Opexa. In earlier threads we talked about dendritic cell vaccines, such as those by Dendreon, Galena, NW Bio. ...

  • Dendreon CEO stepping down for "personal reasons," Is realizing you have scammed a nation of men with prostate cancer a ...

  • Terje: And I am sure everyone in this forum is quite glad you are among the living.If you are really interested in t...

  • Here's a tentative shorting list if anyone is interested. Be careful - I did it kinda fast. Maybe someone can clean it...

  • Ah, JZ. So the idea of taking patients in whom therapy for melanoma has failed....that excites you? Despite the best eff...

  • Hmm - your comments regarding Provenge caught my attention. I got into Dendreon many years ago at $5.48 and sold about ...

  • Kenny, haven't seen the Feuerstein piece, but DC in DCVax is dendritic cell, and I think we can make dendritic cell vacc...

  • To Scott Postma The suggestion to read the irregulars info at SG would possibly save you lots of money. Dr KSS gives hi...

  • You are here, John Davis, to market the newsletter for which you have authored articles supporting ScanCell. My understa...

  • Biocqr: Do you ever get the sense that the FDA is this indolent addled mood-ring of a dysfunctional agency? That it is s...

  • To the insuperable Subra: You probably know this but in case: http://www.nasdaq.com/quotes/institutional-portfolio/sab...

  • Karmaswimswami, thank you for your kind words and your Prostate cancer / Dendreon discussion earlier.I don't want to...

  • I think there are some longs here in Galena (GALE). Because it is on subject, let me say this: what they are doing may b...

  • Alan: it is sobering if you think about it really. It is wrong to predicate an investment on the idea that people are du...

  • One other thing about the Dendreon debate is that it does have object lessons for all of us about the differences betwee...

  • Jack, they have been on a watch list of mine for a while. Please don't take it personally, but I cannot see putting anyt...

  • PS. I have now idea what Dendreon is, but I intend to find out. If i don't like the product i may still buy the stock ...

  • I'm not sure if T cell therapy is the same as dendritic cell therapy, but a couple of companies have caught my eye relat...

  • Here's a"teaser" from Agora's "5-Minute Forecast" Anyone have a clue??? [Paste-in follows]...

  • Here's a"teaser" from Agora's "5-Minute Forecast" Anyone have a clue??? [Paste-in follows...

  • I own shares of an Australian company called Prima Biomed (PRR):ASX? They have a product called C-Vac which, from what I...

  • I seem to remember someone touting that Dendreon was going to come out with horrible results and they urged shorting the...

  • Shoe,If you'd like to turn that turkey into a turducken (http://en.wikipedia.org/wiki/Turducken)you can use the Den...

  • I'm an Alliance Member over at Stansberry & Associates, so I've seen all their products and used most of them. So f...

  • First of all, with regard to Leeb. If I remember correctly, and I am pretty sure I do, his "personal Finance" Newslette...

  • First trade paid for my subscription! Then there was Dendreon, that paid for like 1,000 subscriptions... 300% gain in l...

  • Well, big news from Dendreon this morning -- and if anyone decided to buy puts on Dendreon or sell the shares short, I i...

  • There will be no review committee. Provenge already went to a Biologics division advisory committee on March 29, 2007 t...

  • No, MITI is the better solution for the first one, the "active immunity" one for which I proposed Dendreon....

  • Geez, there goes my teaser for the one I hadn't had a chance to write up yet. Ah, well, I'll write about it later this ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info